Smooth muscle tumor of uncertain malignant potential (STUMP): a clinicopathologic analysis of 26 cases.
Uterine neoplasm
clinicopathologic characteristic
immunohistochemistry
smooth muscle tumor of uncertain malignant potential (STUMP)
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
01
2020
accepted:
06
02
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
epublish
Résumé
To investigate the clinicopathologic features, differential diagnosis, and factors associated with recurrence in patients with smooth muscle tumors of uncertain malignant potential (STUMP). The clinical and pathologic data of STUMP patients diagnosed in Mindong Hospital of Ningde City from 2017 to 2018 were collected and slides reviewed, the high-frequency color Doppler ultrasound and pathological characteristics were observed, and the literature was reviewed. All the STUMP diagnoses were confirmed by slide review. The age of onset was 23-61 years (mean 42.96 years). The main clinical symptoms were leiomyoma of uterus, prolonged menstruation, and increased menstruation. Color Doppler ultrasonography showed hypoechoic uterine wall nodules. The mean follow-up time was 62.9 months (range: 13-96 months). Smooth muscle tumors of undetermined malignant potential (STUMP) in the uterus are one of the rare gynecologic neoplasms. Although not malignant, they should be considered as low malignant potential tumors because they occasionally recur. Six of 13 recurrent tumors recurred in the years following hysterectomy with preservation. These six recurrent tumors are the only ones that had a strong immune response to p16 and p53. In support of early observation, these markers may help predict STUMP behavior. Patients diagnosed with STUMP should be monitored over time.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the clinicopathologic features, differential diagnosis, and factors associated with recurrence in patients with smooth muscle tumors of uncertain malignant potential (STUMP).
METHODS
METHODS
The clinical and pathologic data of STUMP patients diagnosed in Mindong Hospital of Ningde City from 2017 to 2018 were collected and slides reviewed, the high-frequency color Doppler ultrasound and pathological characteristics were observed, and the literature was reviewed.
RESULTS
RESULTS
All the STUMP diagnoses were confirmed by slide review. The age of onset was 23-61 years (mean 42.96 years). The main clinical symptoms were leiomyoma of uterus, prolonged menstruation, and increased menstruation. Color Doppler ultrasonography showed hypoechoic uterine wall nodules. The mean follow-up time was 62.9 months (range: 13-96 months).
CONCLUSIONS
CONCLUSIONS
Smooth muscle tumors of undetermined malignant potential (STUMP) in the uterus are one of the rare gynecologic neoplasms. Although not malignant, they should be considered as low malignant potential tumors because they occasionally recur. Six of 13 recurrent tumors recurred in the years following hysterectomy with preservation. These six recurrent tumors are the only ones that had a strong immune response to p16 and p53. In support of early observation, these markers may help predict STUMP behavior. Patients diagnosed with STUMP should be monitored over time.
Types de publication
Journal Article
Langues
eng
Pagination
818-826Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Am J Surg Pathol. 1994 Jun;18(6):535-58
pubmed: 8179071
Diagn Pathol. 2012 Jan 05;7:1
pubmed: 22217299
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8136-42
pubmed: 25550862
Am J Surg Pathol. 2009 Jul;33(7):992-1005
pubmed: 19417585
Mod Pathol. 2015 Jul;28(7):1001-10
pubmed: 25932961
Arch Gynecol Obstet. 2011 Aug;284(2):483-90
pubmed: 20878171
Gynecol Oncol. 2011 May 1;121(2):328-33
pubmed: 21316747
Oncol Rep. 2017 Jan;37(1):41-47
pubmed: 28004108
Int J Gynecol Pathol. 2008 Jul;27(3):326-32
pubmed: 18580309
Histopathology. 2017 Nov;71(5):743-750
pubmed: 28609585
Gynecol Oncol Rep. 2015 Aug 07;15:1-3
pubmed: 26937476
World J Oncol. 2017 Jun;8(3):76-80
pubmed: 29147439
Histopathology. 2007 Jun;50(7):851-8
pubmed: 17543074
Int J Gynecol Pathol. 2009 Nov;28(6):529-34
pubmed: 19851199
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
Gynecol Oncol. 2009 Jun;113(3):324-6
pubmed: 19342083